Your new go-to full face mask has arrived
Explore how AirTouch™ F40 combines fabric softness with the proven performance1 of AirFit™ F40.
Why AirTouch F40?
- ComfiSoft™ fabric supports resupply: 12% higher cushion resupply based on the number of replacement cushions sold per mask system sold.2
- ComfiSoft fabric supports compliance: AirTouch™ N30i users achieved 6% higher 90-day compliance than AirFit™ N30i users.3
- Easy to fit: 97% of patients rated AirTouch F40 to be easy or very easy to fit and adjust to ensure seal and comfort.1
- Designed for comfort: 91% of patients rated AirTouch F40 comfortable or very comfortable on initial fitting.1
- Built for confidence: 80% of patients did not require assistance to fit the AirTouch F40 mask system to ensure seal and comfort.1
Stock AirTouch F40 today
Order through ROS or your preferred ordering channel to prepare for patient demand.
AirTouch F40 may not be available in all markets. Check local product listings for availability.
This mask contains magnets that may interfere with certain implants or medical devices. Please refer to the User Guide for complete labeling information, including magnet contraindications and warnings.
References
- Source: In an external clinical study, AirTouch F40 demonstrated similar performance to AirFit F40 across seal, overall comfort, ease of use and overall performance. Data on file, ID A5768170.
- Source: Resmed conducted an internal analysis of U.S. AirTouch N30i and AirFit N30i unit-sales data across Major AM, National AM and Regional AM customer tiers, using the AirFit N30i as a benchmark. Comparable launch periods were evaluated, covering FY19 Q3 to FY20 Q4 for AirFit N30i and FY25 Q2 to FY26 Q3 for AirTouch N30i. Cushion resupply was assessed using the cushion-to-mask ratio, calculated as cushion units divided by mask-system plus frame-system units. Across the first six launch quarters, the aggregated cushion-to-mask ratio was 2.61 for AirTouch N30i and 2.33 for AirFit N30i, representing an 11.8% improvement, rounded to 12%. Data on file, ID:A5896103.
- Source: Data is derived from an analysis of new PAP therapy patients in the United States using AirView™ and myAir platforms. Patients were included if myAir™ setup occurred from 7 days before through 14 days after the AirView™ setup date (i.e., −7 to +14 days) and valid mask data were available. Compliance (90-day) was assessed for setups between November 2024 and May 2025. Compliance was defined as PAP use for ≥4 hours per night on ≥70% of nights during any consecutive 30-day period within the first 90 days of therapy, with the AirView setup date counted as day 1. AirTouch™ N30i (85.62%, n=6,160) vs. AirFit™ N30i (79.96%, n=22,898). ID: A5742944
- Source: Resmed internal analysis of AirFit F40, AirTouch F30i and AirTouch F40 fit range. Data on file, ID: A5756043
- Source: Resmed internal testing for the moisture-wicking properties of fabric. Data on file, ID: A5636924.
- Source: Resmed internal analysis of German Healthcare patient and call interaction data shows an association between myAir device registration and up to 21% reduction in support call volume during the first year of therapy (ID: C396710, Resmed Germany, 2024).
- Source: Malhotra et al., “Patient engagement using new technology to improve adherence to positive airway pressure therapy: A retrospective analysis,” CHEST 153. no. no. (Apr 2018): 843-850.